Abstract:Interventions incorporating meditation to address stress, anxiety, and depression, and improve self‐management, are becoming popular for many health conditions. Stress is a risk factor for cardiovascular disease (CVD) and clusters with other modifiable behavioural risk factors, such as smoking. Meditation may therefore be a useful CVD prevention strategy. To determine the effectiveness of meditation, primarily mindfulness‐based interventions (MBIs) and transcendental meditation (TM), for the primary and secondary prevention of CVD. We searched CENTRAL, MEDLINE, Embase, three other databases, and two trials registers on 14 November 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. We included randomised controlled trials (RCTs) of 12 weeks or more in adults at high risk of CVD and those with established CVD. We explored four comparisons: MBIs versus active comparators (alternative interventions); MBIs versus non‐active comparators (no intervention, wait list, usual care); TM versus active comparators; TM versus non‐active comparators. We used standard Cochrane methods. Our primary outcomes were CVD clinical events (e.g. cardiovascular mortality), blood pressure, measures of psychological distress and well‐being, and adverse events. Secondary outcomes included other CVD risk factors (e.g. blood lipid levels), quality of life, and coping abilities. We used GRADE to assess the certainty of evidence. We included 81 RCTs (6971 participants), with most studies at unclear risk of bias. MBIs versus active comparators (29 RCTs, 2883 participants) Systolic (SBP) and diastolic (DBP) blood pressure were reported in six trials (388 participants) where heterogeneity was considerable (SBP: MD ‐6.08 mmHg, 95% CI ‐12.79 to 0.63, I 2 = 88%; DBP: MD ‐5.18 mmHg, 95% CI ‐10.65 to 0.29, I 2 = 91%; both outcomes based on low‐certainty evidence). There was little or no effect of MBIs on anxiety (SMD ‐0.06 units, 95% CI ‐0.25 to 0.13; I 2 = 0%; 9 trials, 438 participants; moderate‐certainty evidence), or depression (SMD 0.08 units, 95% CI ‐0.08 to 0.24; I 2 = 0%; 11 trials, 595 participants; moderate‐certainty evidence). Perceived stress was reduced with MBIs (SMD ‐0.24 units, 95% CI ‐0.45 to ‐0.03; I 2 = 0%; P = 0.03; 6 trials, 357 participants; moderate‐certainty evidence). There was little to no effect on well‐being (SMD ‐0.18 units, 95% CI ‐0.67 to 0.32; 1 trial, 63 participants; low‐certainty evidence). There was little to no effect on smoking cessation (RR 1.45, 95% CI 0.78 to 2.68; I 2 = 79%; 6 trials, 1087 participants; low‐certainty evidence). None of the trials reported CVD clinical events or adverse events. MBIs versus non‐active comparators (38 RCTs, 2905 participants) Clinical events were reported in one trial (110 participants), providing very low‐certainty evidence (RR 0.94, 95% CI 0.37 to 2.42). SBP and DBP were reduced in nine trials (379 participants) but heterogeneity was substantial (SBP: MD ‐6.62 mmHg, 95% CI ‐13.15 to ‐0.1, I 2 = 87%; DBP: MD ‐3.35 mmHg, 95% CI ‐5.86 to ‐0.85, I 2 = 61%; both outcomes based on low‐certainty evidence). There was low‐certainty evidence of reductions in anxiety (SMD ‐0.78 units, 95% CI ‐1.09 to ‐0.41; I 2 = 61%; 9 trials, 533 participants; low‐certainty evidence), depression (SMD ‐0.66 units, 95% CI ‐0.91 to ‐0.41; I 2 = 67%; 15 trials, 912 participants; low‐certainty evidence) and perceived stress (SMD ‐0.59 units, 95% CI ‐0.89 to ‐0.29; I 2 = 70%; 11 trials, 708 participants; low‐certainty evidence) but heterogeneity was substantial. Well‐being increased (SMD 0.5 units, 95% CI 0.09 to 0.91; I 2 = 47%; 2 trials, 198 participants; moderate‐certainty evidence). There was little to no effect on smoking cessation (RR 1.36, 95% CI 0.86 to 2.13; I 2 = 0%; 2 trials, 453 participants; low‐certainty evidence). One small study (18 participants) reported two adverse events in the MBI group, which were not regarded as serious by the study investigators (RR 5.0, 95% CI 0.27 to 91.52; low‐certainty evidence). No subgroup effects were seen for SBP, DBP, anxiety, depression, or perceived stress by primary and secondary prevention. TM versus active comparators (8 RCTs, 830 participants) Clinical events were reported in one trial (201 participants) based on low‐certainty evidence (RR 0.91, 95% CI 0.56 to 1.49). SBP was reduced (MD ‐2.33 mmHg, 95% CI ‐3.99 to ‐0.68; I 2 = 2%; 8 trials, 774 participants; moderate‐certainty evidence), with an uncertain effect on DBP (MD ‐1.15 mmHg, 95% CI ‐2.85 to 0.55; I 2 = 53%; low‐certainty evidence). There was little or no effect on anxiety (SMD 0.06 units, 95% CI ‐0.22 to 0.33; I 2 = 0%; 3 trials, 200 participants; low‐certainty evidence), depression ( -Abstract Truncated-

Modeling the Impact of Transcendental Meditation on Stroke Incidence and Mortality

Prediction-Driven Decision Support for Patients With Mild Stroke: A Model Based on Machine Learning Algorithms

Estimating costs and benefits of stroke management: A population-based simulation model

Meditation and Blood Pressure

Development of Stroke Predictive Model in Community-Dwelling Population: A Longitudinal Cohort Study in Southeast China

Novel Insights on Establishing Machine Learning-Based Stroke Prediction Models Among Hypertensive Adults

A Mechanistic Systems Biology Model of Brain Microvascular Endothelial Cell Signaling Reveals Dynamic Pathway-Based Therapeutic Targets for Brain Ischemia

Cerebral Microbleeds and Stroke Risk after Ischaemic Stroke or Transient Ischaemic Attack: a Pooled Analysis of Individual Patient Data from Cohort Studies.

Estimating Population Burden of Stroke with an Agent-Based Model

Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study

The Health and Economic Impact of Expanding Home Blood Pressure Monitoring

Meditation for the primary and secondary prevention of cardiovascular disease

Impact of Free Hypertension Pharmacy Program and Social Distancing Policy on Stroke: A Longitudinal Study

Enriching the Study Population for Ischemic Stroke Therapeutic Trials Using a Machine Learning Algorithm

Comparing Three Evidence-Based Strategies to Reduce Cardiovascular Disease Burden: An Individual-Based Cardiometabolic Policy Simulation

Current Perspectives on the Use of Meditation to Reduce Blood Pressure

Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study

Abstract WP383: an Economic Model of Improved Acute Stroke Care in the Management of Acute Ischemic Stroke from A State Medicaid Perspective

Using machine learning models to improve stroke risk level classification methods of China national stroke screening

The promising role of Transcendental Meditation in the prevention and treatment of cardiometabolic diseases: A systematic review

The heart-brain axis: A proteomics study of meditation on the cardiovascular system of Tibetan Monks